Telix Pharmaceuticals Q1 Group Revenue Rises; Stock Up
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) reported that its group revenue for the first quarter of fiscal year 2016 increased about 24% to US$230 million, from US$186 million last year.
Precision Medicine revenue for the quarter were US$186 million, up 23% from prior year.
The company reaffirmed its revenue guidance for fiscal year 2026 in a range of US$950 million to US$970 million.
TLX.AX was trading at A$13.54 up A$0.59 or 4.56%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.